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1. INTRODUCTION {#jmv26414-sec-0010}
===============

Since December of 2019, a series of coronavirus pneumonia (coronavirus disease 2019 \[COVID‐19\]) break out in Wuhan City, Hubei Province and other parts of China. Recently it has been identified as a type of beta coronavirus.[^1^](#jmv26414-bib-0001){ref-type="ref"}, [^2^](#jmv26414-bib-0002){ref-type="ref"} Up to 24 March 2020, total 81 773 cases have been confirmed in China, including 67 801 cases in Hubei Province, 50 006 cases in Wuhan City, accumulative 60 323 cured cases in Hubei Province (43 214 cases in Wuhan), and cumulative 3160 deaths in Hubei Province (2524 cases in Wuhan). Other countries include 59 138 cases in Italy, 31 573 cases in the United States, 28 572 cases in Spain, 24 774 cases in Germany, 23 049 cases in Iran, 15 821 cases in France and so on. Considering the highly prevalence and infection, COVID‐19 has been classified as a Class B infectious disease according to the Law of the People\'s Republic of China on the prevention and control of infectious diseases and managed as Class A infectious disease.[^3^](#jmv26414-bib-0003){ref-type="ref"} At the same time, The World Health Organization (WHO) has recently declared COVID‐19 as a public health emergency of international concern,[^4^](#jmv26414-bib-0004){ref-type="ref"} which indicating this COVID‐19 poses a huge threat to global health.

To solve the problem of difficult hospitalization of the patients, By the end of February, the Chinese government totally opened 14 Cabin Hospitals to treat patients confirmed with mild or moderate of COVID‐19. With the effective intervention measures and isolation plans formulated by the government in an efficient manner, most patients received timely diagnosis and treatment.

Since the outbreak of COVID‐19, lots of basic, clinical and epidemiological studies have been reported successively,[^5^](#jmv26414-bib-0005){ref-type="ref"}, [^8^](#jmv26414-bib-0008){ref-type="ref"} and the severity of some cases of COVID‐19 mimicked that of severe acute respiratory syndrome coronavirus (SARS‐CoV),[^6^](#jmv26414-bib-0006){ref-type="ref"}, [^9^](#jmv26414-bib-0009){ref-type="ref"} however, there is no special study on the clinical characteristics of patients and potential risk factors for disease aggravation in Cabin hospital. As a centralized admission hospital for treating COVID‐19, we have treated 571 patients were diagnosed of COVID‐19. This study intends to summarize and analyze the clinical characteristics of the above‐mentioned patients, and explore the risk factors for disease aggravation, and hope to help clinicians to identify patients with poor prognosis at an early stage, and provide early warning function for timely intervention.

2. METHODS {#jmv26414-sec-0020}
==========

2.1. Study design and participants {#jmv26414-sec-0030}
----------------------------------

This was single‐center, retrospective cohort study, and the general information, epidemiological history, incidence, clinical manifestations, laboratory parameters, imaging examinations and treatment of patients confirmed COVID‐19 pneumonia were admitted in Wuhan Stadium Cabin Hospital, the study was approved by the Ethics Committee of Wuhan Stadium Cabin Hospital, and the written informed consent was waived because of the retrospective nature of the study and belongs to emergency medical service.

The diagnosis of COVID‐19 is based on the WHO interim guidance[^10^](#jmv26414-bib-0010){ref-type="ref"} and new coronavirus pneumonia diagnosis and treatment program (6th ed.) (in Chinese),[^11^](#jmv26414-bib-0011){ref-type="ref"} only laboratory‐confirmed positive cases were included in this analysis through Real‐time fluorescence quantitative polymerase chain reaction assay of pharyngeal swab specimens.[^5^](#jmv26414-bib-0005){ref-type="ref"}

2.2. Diagnostic criteria {#jmv26414-sec-0040}
------------------------

### 2.2.1. Epidemiological history {#jmv26414-sec-0050}

(1)Travel history or residence history of Wuhan and surrounding areas or other communities with case reports within 14 days before the onset of illness;(2)History of contact with new coronavirus infected persons (positive nucleic acid test) within 14 days before onset;(3)Have been exposed to patients with fever or respiratory symptoms from Wuhan and surrounding areas, or from communities with case reports;(4)Cluster of diseases.

### 2.2.2. Clinical manifestations {#jmv26414-sec-0060}

(1)Fever and /or respiratory symptoms;(2)Imaging characteristics of pneumonia: multiple small patchy shadows and interstitial changes in the early stage, subsequently developed into bilateral ground‐glass opacity, infiltrates in both lungs. In severe cases, pulmonary consolidation may occur with little pleural effusion;(3)Total number of white blood cells in the early stage of disease was normal or decreased, and the lymphocyte count was decreased.

2.3. Clinical classifications {#jmv26414-sec-0070}
-----------------------------

According to the guideline of New coronavirus pneumonia diagnosis and treatment program, the confirmed patients were divided into the following types: (1) Mild: the clinical symptoms were light, and there was no sign of pneumonia on imaging; (2) moderate: with fever, respiratory tract and other symptoms, imaging suggests pneumonia; (3) severe: coincide with any of the following: (a) respiratory distress, respiration rate (RR) ≥ 30 times /min; (b) the oxygen saturation ≤93% in the resting state; (c) PaO~2~/FiO~2~ ≤ 300mm Hg (1mm Hg = 0.133 kPa); (4) Critically ill: coincide with any of the following: (a) respiratory failure occurs and mechanical ventilation is required; (b) shock; (c) the patient develops other organ failure and needs ICU monitoring and treatment. The mild and moderate types were collected as subjects in our study.

2.4. Real‐time reverse transcription polymerase chain reaction assay for novel coronavirus {#jmv26414-sec-0080}
------------------------------------------------------------------------------------------

Reverse transcription polymerase chain reaction assays were performed in accordance with the protocol established by the WHO.[^12^](#jmv26414-bib-0012){ref-type="ref"} Throat swab samples were collected for extracting 2019‐nCoV (novel coronavirus) RNA from patients suspected of having 2019 nCoV infection. After collection, the throat swabs were placed in to a collection tube with150 μL of virus preservation solution, and total RNA was extracted within 2 hours using the respiratory sample RNA isolation kit (Zhongzhi, Wuhan, China). The nucleic acid testing was performed by a third institution recognized by Chinese Center for Disease Control and Prevention, and details regarding laboratory confirmation processes are provided in the Supplementary Appendix (Table S1).

2.5. Statistical analysis {#jmv26414-sec-0090}
-------------------------

Continuous variables with normal distribution were expressed as mean ± standard deviation; non‐normal continuous variables were reported as median (interquartile range \[IQR\]). For *P* value, the Mann‐Whitney *U* test were used for analyzing the normally distributed continuous variables, and the Kruskal‐Wallis test for non‐normally distributed data. The categorical variables were presented as percentage and analyzed by the *χ* ^2^ test or the Wilcoxon rank‐sum test. All statistical analyses were performed with Stata version 14.2 for Mac (StataCorp, College Station, TX), and *P* value less than .05 was considered statistically significant. Multiple logistic regression models were used to identify factors that influenced outcomes and presented as odds ratios (ORs) and 95% confidence intervals (CIs). The differences in baseline characteristics among nonanemic and anemic patients entered into the multivariate regression. Results were reported follow that all associations as ORs in logistic regression models, with their corresponding 95% CIs.

3. RESULTS {#jmv26414-sec-0100}
==========

In our study, 571 cases confirmed with COVID‐19 in Wuhan Stadium Cabin Hospital were involved (Figure [1](#jmv26414-fig-0001){ref-type="fig"}), all of these cases had no epidemic history of contacting with seafood market of South China directly. Among them, 293 were females (51.56%), 278 were males (48.70%), the median age is 50 years (IQR, 38.0‐59.0), 26 patients (4.55%) were transferred to a designated specialized hospital for further treatment within 72 hours of admission due to the aggravation of the disease. The time points of transferred patients mainly between 36 and 48 hours (65.38%) (Figure [2](#jmv26414-fig-0002){ref-type="fig"}). There were 14 cases (53.85%) of transferred patients with a history of smoking, and 122 cases (22.39%) in stable patients. Hypertension, diabetes, and coronary heart diseases were the main comorbidities both in transferred patients (26.92%, 15.38%, 15.38%) and in stable patients (9.51%, 2.38%, 1.65%), The main clinical symptoms were fever, cough, and dyspnea, which accounted for 15 (57.69%), 20 (76.90%), and 16 (61.54%) cases in transferred patients, and 284 (51.92%), 382 (70.09%), and 89 (16.27%) cases in stable patients. Computed tomography (CT) scanning showed consolidation and interstitial abnormalities were obviously seen in transferred patients (38.46%, 61.54%) than that in stable patients(5.32%, 8.25%) (Table [1](#jmv26414-tbl-0001){ref-type="table"}). The other symptoms included fatigue, muscle aches, chest tightness, headache, diarrhea, etc. There was no significant difference between the transferred and stable patients.

![Flow diagram of clinical trial in the study. COVID‐19, coronavirus disease 2019](JMV-9999-na-g001){#jmv26414-fig-0001}

![Number of transferred patients at different timepoints](JMV-9999-na-g002){#jmv26414-fig-0002}

###### 

Clinical characteristics of 571 patients infected with COVID‐19

  Characteristics                   Total patients (N = 571)   Transferred patients (N = 26)   Stable patients (N = 545)   *P* value
  --------------------------------- -------------------------- ------------------------------- --------------------------- ----------------------------------------------------------
  Age, y                                                                                                                   
  Median (IQR)                      50.0 (38.0‐59.0)           50.0 (31.0‐60.25)               50.0 (38‐58.5)              .711
  Sex: 0.845                                                                                                               
  Female                            293/571 (51.30%)           12/26 (46.20%)                  281/545 (51.60%)            
  Male                              278/571 (48.70%)           14/26 (53.80%)                  264/545 (48.40%)            
  Smoking history                                                                                                          
  Former smoker                     56/571 (9.80%)             10/26 (38.46%)                  46/545 (8.44%)              .0001[\*\*\*](#jmv26414-tbl1-note-0004){ref-type="fn"}
  Current smoker                    80/571 (14.0%)             4/26 (15.38%)                   76/545 (13.94%)             .979
  Comorbidities                                                                                                            
  Hypertension                      55/571 (9.63%)             7/26 (26.92%)                   52/54 5(9.51%)              .0234[\*](#jmv26414-tbl1-note-0002){ref-type="fn"}
  Diabetes                          17/571 (2.98%)             4/26 (15.38%)                   13/545 (2.38%)              .0007[\*\*\*](#jmv26414-tbl1-note-0004){ref-type="fn"}
  Coronary heart disease            12/571 (2.10%)             3/26 (15.38%)                   9/545 (1.65%)               .002[\*\*](#jmv26414-tbl1-note-0003){ref-type="fn"}
  Chronic kidney disease            1/571 (0.18%)              0                               1/545 (0.18%)               .976
  Gout                              2/57 1 (0.35%)             0                               2/545 (0.37%)               .953
  Signs and symptoms on admission                                                                                          
  Fever ≥37.3°C                     299/571 (52.36%)           15/26 (57.69%)                  284/545 (51.92%)            .856
  Cough                             402/571 (70.40%)           20/26 (76.9%)                   382/545 (70.09%)            .757
  Fatigue, muscle aches             95/571 (16.63%)            8/26 (30.77%)                   77/545 (14.77%)             .077
  Dyspnea                           105/571 (18.39%)           16/26 (61.54%)                  89/545 (16.27%)             \<.0001[\*\*\*](#jmv26414-tbl1-note-0004){ref-type="fn"}
  Headache                          55/571 (9.63%)             3/26 (11.54%)                   52 /545 (9.51%)             .945
  Sore throat                       28/571 (4.90%)             2/26 (7.69%)                    26/545 (4.75%)              .797
  Nasal congestion                  17/571 (2.98%)             2/26 (7.69%)                    15/545 (2.75%)              .351
  Chest tightness                   100/571 (17.51%)           5/26 (19.23%)                   95/545 (17.37%)             .973
  Diarrhea                          51/571 (8.93%)             2/26 (7.69%)                    49/545 (8.96%)              .975
  Nausea or vomiting                21/571 (3.68%)             2/26 (7.69%)                    19/545 (3.49%)              .538
  Abnormalities on chest CT                                                                                                
  Ground‐glass opacity              277/571 (48.51%)           8/26 (30.76%)                   276/545 (50.64%)            .141
  Normal density shadow             108/571 (18.91)            0                               108/545 (19.82%)            .007[\*\*](#jmv26414-tbl1-note-0003){ref-type="fn"}
  Consolidation                     39/571 (6.83%)             10/26 (38.46%)                  29/545 (5.32%)              \<.0001[\*\*\*](#jmv26414-tbl1-note-0004){ref-type="fn"}
  Nodular lesion                    93/571 (16.29%)            6/26 (23.07%)                   87/545 (15.96%)             .631
  Interstitial abnormalities        61/571 (10.68%)            16/26 (61.54%)                  45/545 (8.25%)              \<.0001[\*\*\*](#jmv26414-tbl1-note-0004){ref-type="fn"}
  Treatments                                                                                                               
  Antibiotic treatment              571/571 (100%)             26/26 (100%)                    545/545 (100%)              
  Antiviral treatment               571/571 (100%)             26/26 (100%)                    545/545 (100%)              
  Traditional Chinese medicine      571/571 (100%)             26/26 (100%)                    545/545 (100%)              
  Hormone therapy                   26/571 (4.55%)             26/26 (100%)                    0                           \<.0001[\*\*\*](#jmv26414-tbl1-note-0004){ref-type="fn"}
  Intranasal oxygen inhalation      38/571 (6.65%)             26/26 (100%)                    135/545 (24.77%)            .0002[\*\*\*](#jmv26414-tbl1-note-0004){ref-type="fn"}
  Mechanical ventilation            Unknown                    Unknown                         0                           
  ECMO                              Unknown                    Unknown                         0                           
  Clinical outcome                                                                                                         
  Discharged                        Unknown                    Unknown                         545/545 (100%)              
  Remained in hospital              Unknown                    Unknown                         0                           
  Died                              Unknown                    Unknown                         0                           

Abbreviations: COPD, chronic obstructive pulmonary disease; COVID‐19, coronavirus disease‐19; CT, computed tomography; ECMO, extracorporeal membrane oxygenation; IQR, interquartile range.

*P*  \< .05.

*P*  \< .01.

*P*  \< .001.

John Wiley & Sons, Ltd.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

Laboratory results showed the white blood cell count, neutrophils and lymphocytes were all lower in transferred patients than stable patients, whereas, lactate dehydrogenase (LDH) and C‐reactive protein (CRP) were both in significantly higher in transferred patients than stable patients. No significant difference of the other laboratory results between in the two groups patients (Table [2](#jmv26414-tbl-0002){ref-type="table"}).

###### 

Laboratory tests of 571 patients infected with COVID‐19

  Variables                          Total patients (N = 571)   Transferred patients (N = 26)   Stable patients (N = 545)   *P* value
  ---------------------------------- -------------------------- ------------------------------- --------------------------- --------------------------------------------------------
  Blood routine (IQR)                                                                                                       
  WBC count (x10^9^/L)               5.55 (3.94, 8.11)          4.47 (3.44, 5.83)               5.65 (4.06, 8.13)           .007[\*\*\*](#jmv26414-tbl2-note-0004){ref-type="fn"}
  NEU count (x10^9^/L)               4.17 (3.00, 5.87)          3.50 (2.55, 4.48)               4.21 (3.03, 5.95)           .030[\*](#jmv26414-tbl2-note-0002){ref-type="fn"}
  LYM count (x10^9^/L)               0.72 (0.42, 1.10)          0.53 (0.41, 0.72)               0.74 (0.43, 1.13)           .004[\*\*\*](#jmv26414-tbl2-note-0004){ref-type="fn"}
  Hb, g/L                            134.0 (125.0, 144.0)       142.0 (130.3, 145.0)            134.0 (125.0, 143.5)        .142
  PLT count (x10^9^/L)               256.0 (226.0, 289.0)       247.0 (224.8, 287.3)            256.0 (226.0, 289.0)        .637
  Coagulation (IQR)                                                                                                         
  PT, s                              11.20 (10.40, 11.60)       11.20 (10.30, 11.53)            11.20 (10.42, 11.60)        .716
  APTT, s                            34.22 (29.78, 36.50)       31.69 (29.13, 34.79)            34.44 (29.78, 36.76)        .133
  D‐D, ng/mL                         189.5 (144.5, 306.2)       198.0 (148.0, 271.0)            198.0 (148.0, 263.5)        .878
  Myocardial enzymes (IQR)                                                                                                  
  CK, IU/L                           235.3 (178.2, 290.3)       234.6 (170.1, 264.6)            235.3 (178.2, 290.8)        .744
  LDH, U/L                           287.7 (210.5, 373.2)       432.7 (411.1, 496.6)            287.5 (205.0, 354.2)        \<.0001[\*\*](#jmv26414-tbl2-note-0003){ref-type="fn"}
  CK‐MB, U/L                         19.23 (16.43, 22.45)       19.71 (18.05, 22.68)            19.22 (16.43, 22.45)        .345
  Biochemical indicators (IQR)                                                                                              
  ALT, IU/L                          34.56 (26.34, 42.34)       36.94 (30.01, 43.76)            34.56 (26.23, 42.34)        .345
  AST, IU/L                          32.12 (24.54, 36.12)       31.30 (24.35, 34.32)            32.12 (24.54, 36.43)        .530
  ALB, g/L                           44.57 (39.81, 48.32)       43.90 (38.76, 47.57)            44.57 (39.89, 48.32)        .2141
  Cr, µmol/L                         87.34 (76.45, 98.60)       88.00 (76.31, 98.63)            87.34 (76.45, 98.70)        .8198
  BUN, mmol/L                        6.54 (5.44, 7.45)          6.43 (5.42, 7.50)               6.54 (5.44, 7.45)           .7606
  Indicators of inflammation (IQR)                                                                                          
  CRP, mg/L                          39.32 (26.71, 67.32)       60.73 (42.41, 77.43)            38.33 (25.85, 67.23)        .002[\*\*\*](#jmv26414-tbl2-note-0004){ref-type="fn"}
  PCT, ng/ML                         0.031(0.019, 0.043)        0.027 (0.019, 0.043)            0.031 (0.019, 0.043)        .5296

Abbreviations: ALB, Albumin; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BUN, urea nitrogen; CK, creatine kinase; CK‐MB, creatine kinase‐MB; COVID‐19, coronavirus disease‐19; Cr, creatinine; CRP, C‐reactive protein; D‐D, DD dimers; Hb, hemoglobin; IQR, interquartile range; LDH, lactate dehydrogenase; LYM, lymphocytes; NEU, neutrophils; PCT, procalcitonin; PLT, platelets; PT, prothrombin time; WBC, white blood cells.

*P*  \< .05.

*P*  \< .01.

*P*  \< .001.

John Wiley & Sons, Ltd.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

In univariable analysis, odds of disease aggravation were higher with diabetes or coronary heart disease or hypertension (Table [1](#jmv26414-tbl-0001){ref-type="table"}). Former smoker history, lymphopenia, LDH, and CRP were also associated with disease aggravation (Tables [1](#jmv26414-tbl-0001){ref-type="table"} and [2](#jmv26414-tbl-0002){ref-type="table"}).

We included 571 patients with complete data for all variables (26 transferred patients and 545 stable patients) in the multivariable logistic regression model. We found that former smoker history, diabetes, dyspnea, consolidation, and interstitial abnormalities of CT scanning, lymphopenia, and elevated of CRP were associated with increased odds of disease aggravation (Table [3](#jmv26414-tbl-0003){ref-type="table"}).

###### 

Risk factors associated with transferred hospital

  Characteristics                Univariable analyses   Multiple variable regression   
  ------------------------------ ---------------------- ------------------------------ -------------------------------------------------------
  Age, y, median (IQR)           .711                                                  
  Female                         .845                                                  
  Male                                                                                 
  Former smoker                  .0001                  14.53 (3.18, 66.20)            .001[\*\*](#jmv26414-tbl3-note-0003){ref-type="fn"}
  Current smoker                 .979                                                  
  Hypertension                   .0234                  0.75 (0.12, 4.59)              .755
  Diabetes                       .0007                  22.64 (2.30, 223.022)          .0008[\*](#jmv26414-tbl3-note-0002){ref-type="fn"}
  Coronary heart disease         .002                   6.75 (0.629, 72.61)            .115
  Chronic kidney disease         .976                                                  
  Gout                           .953                                                  
  Fever ≥37.3°C                  .856                                                  
  Cough                          .757                                                  
  Fatigue, muscle aches          .077                                                  
  Dyspnea                        \<.0001                10.93 (2.95, 40.45)            \<.0001[\*](#jmv26414-tbl3-note-0002){ref-type="fn"}
  Headache                       .945                                                  
  Sore throat                    .797                                                  
  Nasal congestion               .351                                                  
  Chest tightness                .973                                                  
  Diarrhea                       .975                                                  
  Nausea or vomiting             .538                                                  
  Ground‐glass opacity           .141                                                  
  No abnormal density shadow     .007                                                  
  Consolidation                  \<.0001                15.52 (2.86, 84.24)            .001[\*\*](#jmv26414-tbl3-note-0003){ref-type="fn"}
  Nodular lesion                 .631                                                  
  Interstitial abnormalities     \<.0001                13.40 (4.05, 44.31)            \<.0001[\*](#jmv26414-tbl3-note-0002){ref-type="fn"}
  Antibiotic treatment                                                                 
  Antiviral treatment                                                                  
  Traditional Chinese medicine                                                         
  Lymphocyte counting                                   0.89 (0.81, 0.97)              .008[\*\*](#jmv26414-tbl3-note-0003){ref-type="fn"}
  Elevated LDH                                          5.01 (1.00, 25.35)             .05
  CRP (\>40 mg/L)                \<.0001                5.03 (1.41, 19.16)             .013[\*\*\*](#jmv26414-tbl3-note-0004){ref-type="fn"}
  Hormone therapy                \<.0001                                               
  Intranasal oxygen inhalation                                                         
  Mechanical ventilation                                                               
  ECMO                                                                                 
  Discharged                                                                           
  Remained in hospital                                                                 
  Died                                                                                 

Abbreviations: CI, confidence interval; CRP, C‐reactive protein; ECMO, extracorporeal membrane oxygenation; IQR, interquartile range; LDH, lactate dehydrogenase; OR, odds ratio.

*P*  \< .05.

*P*  \< .01.

*P*  \< .001.

John Wiley & Sons, Ltd.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

All patients were treated with a single antibiotic moxifloacin, antiviral therapy (oseltamivir/arbidol), and traditional Chinese medicine (Lian hua qing wen capsule). Twenty‐six patients (4.55%) were transferred to a designated specialized hospital for further treatment within 72 hours of admission due to the aggravation of the disease. In stable patients, 135 patients (24.77%) used intranasal oxygen inhalation, and no patient used intravenous drug and invasive ventilator.

Clinical outcomes of the transferred patients were unknown due to transferred to another hospital and lost connection, according to the discharge standard, up to 10 March, 545 cases (100%) of stable patients were discharged from the Cabin hospital, and no patient died. The average hospital stay for discharge patients was 15 days.

4. DISCUSSION {#jmv26414-sec-0110}
=============

This study was a single‐center retrospective cohort study that reported the clinical characteristics of patients diagnosed with COVID‐19 and potential risk factors for disease aggravation in Wuhan Stadium Cabin Hospital. With the epidemic development of CVIOD‐19 pneumonia, the number of patients diagnosed as COVID‐19 in Wuhan has increased sharply since January. To solve the problem of difficult hospitalization of the patients, By the end of February, the Chinese government totally opened 14 Cabin Hospitals to treat patients confirmed with mild or moderate of COVID‐19. With the effective intervention measures and isolation plans formulated by the government in an efficient manner, most patients received timely diagnosis and treatment. Among the patients admitted to Wuhan Stadium Cabin Hospital, except for 26 patients who were exacerbated and transferred to the designated special hospital for further treatment, the remaining 545 patients showed mild and common symptoms, and improved significantly after symptomatic treatment.

In our study, we identified several risk factors for disease aggravation in cabin hospital with COVID‐19. Through univariable analysis, odds of disease aggravation were higher with diabetes or coronary heart disease or hypertension. Former smoker history, lymphopenia, LDH, and CRP were also associated with disease aggravation. In the multivariable logistic regression model, we found that former smoker history, diabetes, dyspnea, consolidation and interstitial abnormalities of CT scanning, lymphopenia and elevated of CRP were associated with increased odds of disease aggravation.

Earlier reports on SARS‐CoV‐2 and COVID‐19 suggested that they were similar to SARS and Middle East respiratory syndrome (MERS) in the early years, with most patients presented with fever, dry cough, fatigue, and dyspnea,[^5^](#jmv26414-bib-0005){ref-type="ref"}, [^13^](#jmv26414-bib-0013){ref-type="ref"}, [^14^](#jmv26414-bib-0014){ref-type="ref"} our study also found that fever dry cough and dyspnea accounted for 15 (57.69%), 20 (76.90%), and 16 (61.54%) cases in transferred patients, and 284 (51.92%), 382 (70.09%), and 89 (16.27%) cases in stable patients. However, in this study, the typical symptoms of upper respiratory tract infection, such as runny nose, sneezing, and sore throat are not common, which are different from the previously reported SARS and MERS related onset symptoms.[^13^](#jmv26414-bib-0013){ref-type="ref"}, [^14^](#jmv26414-bib-0014){ref-type="ref"}

Older age has been reported as an important independent predictor of mortality not only in SARS and MERS,[^15^](#jmv26414-bib-0015){ref-type="ref"}, [^16^](#jmv26414-bib-0016){ref-type="ref"} but also in COVID‐19,[^17^](#jmv26414-bib-0017){ref-type="ref"} however, in our study, age was not a risk factor for disease aggravation, this may be related to the majority of mild and moderate patients admitted to the cabin hospital.

Although smoking history was not an independent risk factor for disease exacerbations in previous studies, however, in our multivariate regression analysis, former smoker history was associated with disease aggravation, which may have an impact on breathing, and further research is needed to determine whether smoking is an independent risk factor for assessing of disease prognosis.

It is well known that diabetes is an independent risk factor for a variety of diseases, in previous studies, diabetes was considered as a risk factor for disease exacerbation of COVID‐19,[^18^](#jmv26414-bib-0018){ref-type="ref"}, [^19^](#jmv26414-bib-0019){ref-type="ref"} through our regression analysis, it was also found that patients with diabetes had higher rate of transferred, previous data suggested that ACE2 expression was increased in diabetes and treatment with ACE inhibitors and ARBs increased ACE2 expression, however, whether the specific mechanism of diabetes affecting prognosis of COVID‐19 through the expression of ACE2 still need further study.

Our study has some limitations. First, due to the retrospective study design, not all laboratory tests were done in all patients, which might be underestimated in predicting disease condition. Second, the results and prognosis of 26 patients were unknown due to transferred to a designated specialized hospital for further treatment, last but not least, interpretation of our findings might be limited by the sample size. However, by including the number of cases in cabin hospital, we believe our study population is representative disease condition of mild and moderate of COVID‐19.

In summary, we hope the potential risk factors of former smoker history, diabetes, dyspnea, consolidation and interstitial abnormalities of CT scanning, lymphopenia and elevated of CRP could help clinicians to identify patients with poor prognosis at an early stage, and provide early warning function for timely intervention.
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